Transcriptional activation of the cyclin D1 gene is a key step in cell proliferation. Accordingly, cyclin D1 overexpression is frequently an early step in neoplastic transformation, particularly in mammary epithelium. Numerous studies have linked elevated cyclin D1 promoter activity to a sustained activation of the ERK1/2 cascade. Here we show that the ERK5 cascade, a distinct mitogeninduced MAPK pathway, can also drive cyclin D1 expression. In CCL39 cells, serum induces a strong, prolonged peak of ERK1/2 and ERK5 phosphorylation, and subsequently elevates cyclin D1 mRNA and protein levels. Overexpression of constitutively active MEK5 and wt ERK5 induces a cyclin D1 reporter gene (D1 À973-luciferase) at least as well as constitutively active MEK1. Activation is blocked by kinase-dead mutants of ERK5 and ERK2, respectively. Mutation of the CRE at À50 in the cyclin D1 promoter decreases activation by the ERK5 but not the ERK1/2 cascade. Importantly, expression of kinase-dead ERK5 diminishes endogenous cyclin D1 protein induction by serum in CCL39 cells and the breast cancer cell lines MCF-7 and HS579. These data identify the cyclin D1 gene as a novel target of the ERK5 cascade, an observation with important implications in cancers involving cyclin D1 deregulation.
Introduction
The protein encoded by the cyclin D1 gene regulates transit of the G1 phase of the cell cycle as an integral component of the cyclin D/cdk4 kinase complex that targets the retinoblastoma protein (pRb) (Sherr and Roberts, 1999) . This leads to the release of pRb from DNA-bound complexes containing the E2F family of transcriptional regulatory proteins, and thereby switches these complexes from repressors to activators (Sherr and Roberts, 1999) . While the essential molecular steps involved in cyclin D1-dependent control of G 1 phase genes have been established in cultured cells, particularly those of tumoral origin, these findings clearly reflect the important role played by the cyclin D1 protein in vivo. The cyclin D1 gene was originally cloned from B-cell lymphomas as Bcl-1 (Withers et al., 1991) and from parathyroid adenomas as PRAD1 (Motokura et al., 1991) , and subsequently has been implicated in a wide variety of cancers. In primary breast carcinoma, the cyclin D1 gene is amplified in 20% of tumors (Dickson et al., 1995) , while over 50% show overexpression of the protein (Bartkova et al., 1994; McIntosh et al., 1995) . Overexpression can occur at very early stages of cancer progression, and, once acquired, high levels of cyclin D1 persist even after metastasis (Bartkova et al., 1994; Gillett et al., 1996) . Consistent with the key role this suggests, mice engineered to overexpress cyclin D1 die from breast cancer (Wang et al., 1994) , while mammary tissue from mice lacking cyclin D1 is insensitive to the transforming effects of activated ras and neu but is still sensitive to other oncogenes, such as myc and wnt-1 (Yu et al., 2001) .
Given the central role of cyclin D1 in the cell cycle, it is not surprising that its expression is regulated at multiple levels. These include transcriptional induction, mRNA stability, translational control and protein turnover (Hamel and Hanley-Hyde, 1997) . Transcriptional regulation of cyclin D1 can be reproduced in transient transfection assays using a promoter fragment that spans the sequences from À973 to þ 139 relative to the mRNA initiation site (Herber et al., 1994) . Despite considerable disparity between different experimental systems, several cis-acting elements are clearly implicated in promoter control: an AP-1 site, an Ets (or STAT) consensus sequence, several NF-kB sites, a series of SP-1-like sequences, an E2F consensus binding site and a CRE that is surrounded by TCF/LEF sites (Albanese et al., 1995; Watanabe et al., 1998; Hinz et al., 1999; Lee et al., 1999; Tetsu and McCormick, 1999; Nagata et al., 2001) . Transcriptional induction has been attributed to each of these sites. Notably, the transcription factors that bind to most of these sites are phosphorylated and thus activated by various intracellular signaling cascades, suggesting a convergence of these pathways on the cyclin D1 promoter.
A key mediator of proliferative signaling is the Ras/ Raf/MEK/ERK/RSK-MSK cascade, and accordingly a sustained activation of this pathway generated ectopically has been linked to cyclin D1 induction and cell cycle progression (Lavoie et al., 1996; Balmanno and Cook, 1999) . However, serum-stimulated ERK activation in culture cells reaches its peak long before cyclin D1 activation, strongly suggesting that the effect on the cyclin D1 promoter is indirect or involves another, similar signaling pathway. One potential candidate is the MEK5/ERK5 cascade, which is activated by growth signals, sensitive to the same pharmacological inhibitors as the MEK1-2/ERK1-2 signaling module, and is also essential for proliferation in certain cell lines (Kato et al., 1998; Mody et al., 2001; Esparis-Ogando et al., 2002) . Similar to the ERK pathway, the ERK5 cascade also phosphorylates a distinct set of transcription factors implicated in cell cycle entry (English et al., 1998; Kato et al., 2000) . EGF-driven ERK5 activation is independent of Ras and is required for proliferation in the breast epithelial cell line MCF10A (Kato et al., 1998) . Thus, this pathway is a potential mediator of cyclin D1 induction by growth factors in breast cancer cells.
Our aim was to test the role of ERK5 in a system where ERK1/2 have been implicated in cyclin D1 activation. We chose the Chinese hamster fibroblast cell line CCL39, in which cotransfection experiments have linked ERK1/2 activation to expression of a cyclin D1 reporter gene, an induction that was sensitive to dominant-negative forms of both MEK1 and ERK2 (Lavoie et al., 1996) . Accordingly, Balmanno and Cook (1999) found that sustained ERK1/2 activity was required for full cyclin D1 induction, which was blocked by PD98059, a pharmacological inhibitor of MEK1. However, PD98059 blocks ERK5 as well as ERK1/2 (Mody et al., 2001) . Based on this, we explored the effects of the ERK1/2 versus the ERK5 signaling cascades on activation of cyclin D1 reporter genes in CCL39 cells. Our data demonstrate that serum induces prolonged phosphorylation of endogenous ERK1/2 and ERK5 that overlaps with the expression of cyclin D1. In transient transfections using constitutively active mutants of the MAPK-activating kinases MEK1 or MEK5, the ERK1/2 and ERK5 cascades activate a cyclin D1-luciferase construct to the same extent. This induction is blocked by kinase-dead mutants of ERK2 and ERK5, respectively. Notably, the latter also inhibits serum induction of the endogenous cyclin D1 protein. Mutation of the CRE only blocks activation by the ERK5 cascade. This requires CREB, but is independent of CREB phosphorylation on Ser133. Surprisingly, mutation of the AP-1 site does not compromise reporter activation by either the ERK1/2 or ERK5 cascades. Thus, the cyclin D1 promoter appears to be targeted in different ways by these two MAPK cascades. Finally, we find that expression of kinase-dead ERK5 strongly reduces serum induction of the cyclin D1 protein in several breast cancer cell lines, thereby indicating that the ERK5 cascade is an important component in cyclin D1 regulation in this context as well.
Results

Kinetics of cyclin D1 and MAPK induction in CCL39 cells
In CCL39 cells, transfected ERK1 enhances activation of a cyclin D1 reporter gene (Lavoie et al., 1996) . To investigate this link at the endogenous level, we first examined the kinetics of cyclin D1, ERK1/2 and ERK5 protein expression in CCL39 cells to see whether there was a correlation between MAPK activation and cyclin D1 induction. To diminish ERK signaling to undetectable levels, we found it necessary to treat nearly confluent cells with medium containing 0.5% serum for 24 h, followed by 18 h in medium lacking serum. Cells were then stimulated with 20% serum and lysed at various time points to obtain total cellular protein and RNA. Cyclin D1 mRNA levels progressively increased 4-8 h postinduction (Figure 1a) . Correspondingly, cyclin D1 protein levels were low under starved conditions and increased 4 h after stimulation (Figure 1b) . To follow the activation of ERK1, 2 and 5, we analysed Western blots with antibodies directed against the doubly phosphorylated, active versions of each kinase. Phospho-ERK1 and 2 were barely detectable after extended serum deprivation. Serum induction led to a rapid, robust increase in ERK1 and 2 phosphorylation that subsequently diminished, but did not disappear (Figure 1b) . A low level of ERK5 phosphorylation was present in starved cells, and was rapidly induced in response to serum (Figure 1b ). Phospho-ERK5 was also visualized by its slower mobility under these electrophoresis Extensively starved cells were treated with serum and total cellular RNA was prepared at various points thereafter. Cyclin D1 and gapdh mRNAs were measured by Northern blot analysis. The bar graph presents the hybridization signals as quantitated using a phosphorimager. (b) Extensively starved cells were treated with serum and whole-cell extracts were prepared at the times indicated. Western blots were incubated with antibodies specific for cyclin D1, ERK1/2, phospho-ERK1/2, phospho-ERK5 and ERK5, as indicated beside each panel conditions (ERK5 control panel, Figure 1b ), as previously shown (Kato et al., 1998) . Notably, phospho-ERK5 remained detectable throughout cyclin D1 induction (Figure 1b) . Kinase levels did not vary during serum treatment (Figure 1b ).
ERK1/2 and ERK5 pathways activate cyclin D1 transcription
The above data showed that both ERK1/2 and ERK5 are activated prior to induction of the endogenous cyclin D1 promoter. To examine their potential role in cyclin D1 transcriptional regulation, we transiently transfected CCL39 cells with expression vectors coding for MEK1SS3 and MEK5D, constitutively activated components of each ERK cascade. MEK1SS3 is the MAPK kinase that selectively targets ERK1/2, while MEK5D selectively activates ERK5 (Kato et al., 1997) . These vectors gave rise to similar levels of expression for the two kinases in these cells (Figure 2e, upper panel) .
To confirm that MEK5D is active in CCL39 cells, we first tested its ability to induce a cotransfected c-jun reporter construct, which is targeted by ERK5 (Kato et al., 1997; Marinissen et al., 1999) . Overexpression of MEK5D alone had a weak effect (Figure 2a ), despite the presence of endogenous ERK5 (Figure 1b ). Cotransfection of an ERK5 expression construct enhanced induction of the c-jun reporter by MEK5D, while a mutant of ERK5 that cannot be phosphorylated and activated by MEK5 (ERK5AEF) blocked activation ( Figure 2a ). The expression vector for wt ERK5 had no effect on its own (data not shown). Both kinases were expressed at equivalent levels in transfected cells (Figure 2e, bottom panel) . Thus, the ERK5 cascade can be activated in CCL39 cells, but requires overexpression of both activated MEK5 and ERK5.
ERK5 activates the c-jun promoter by phosphorylation of MEF2C (Kato et al., 1997; Marinissen et al., 1999) . In order to test the specificity of the ERK5 cascade expression constructs in CCL39 cells, we compared their ability to activate c-jun reporter genes bearing mutations in the ATF or the MEF2C binding sites (Han and Prywes, 1995) . Increasing amounts of MEK5D and ERK5 expression vectors induced the mutant ATF and wt promoters to similar levels, while mutation of the MEF2C binding site strongly reduced activation but surprisingly did not fully block it (Figure 2b ). These data suggest that another site in the c-jun promoter may confer weak activation by the ERK5 cascade in these cells. Taken together, these data demonstrate the specificity of the MEK5-ERK5 signaling cascade upon transfection in CCL39 cells.
We next used indirect immunofluoresence to determine whether the ectopically expressed, activated kinases could induce expression of the endogenous cyclin D1 protein in CCL39 cells. In nontransfected cells, cyclin D1 protein is detectable in a subset of asynchronously growing cells but not in cells subjected to serum starvation ( Figure 3a ). Serum stimulation increased cyclin D1 protein expression in the vast majority of cells (Figure 3a ). To activate selectively the two MAPK cascades, CCL39 cells were transfected with expression vectors encoding MEK1SS3 or MEK5D in combination with wt ERK5. The two activated MAPKKs strongly elevated endogenous cyclin D1 protein levels relative to the neighboring nontransfected cells (Figure 3b ), while cotransfection of MEK5D with kinase-dead ERK5AEF blocked this increase. These results demonstrated that ectopically expressed MEK1SS3 and MEK5D/ERK5 activated the expression of cyclin D1 protein. More importantly, serum induction of cyclin D1 protein was strongly reduced in cells expressing FLAG-ERK5AEF, but not in neighboring untransfected cells (Figure 3c ). This demonstrates that the ERK5 cascade is a key component in serum signaling to the endogenous cyclin D1 gene.
To evaluate the ability of the two cascades to induce transcription of the cyclin D1 promoter, we transfected the kinase expression vectors together with the cyclin D1 reporter gene D1 À973-luc, which contains the luciferase gene under the control of the cyclin D1 promoter fragment spanning from À973 to þ 139. As previously described (Lavoie et al., 1996) , MEK1SS3 led to a threefold increase in cyclin D1 reporter activation ( Figure 2c ). Notably, this increase did not require cotransfection of ERK1 or ERK2 expression vectors (Lavoie et al., 1996 ; data not shown). In contrast, the expression vector for MEK5D did not stimulate the cyclin D1 reporter gene unless cotransfected with the vector encoding ERK5 (Figure 2c and data not shown). We then tested whether cyclin D1 activation was blocked by kinase-dead forms of these MAPKs: ERK5AEF, ERK1(K71R) or ERK2(K52R), labeled as KD-ERK1 and KD-ERK2, respectively. Control immunoblots showed that all the MAPKs were expressed at similar levels in transfected cells ( Figure 2e , middle and bottom panels). Similar to the c-jun reporter described above, kinase-dead ERK5 reversed MEK5D-driven activation of the cyclin D1 reporter gene ( Figure 2c ). KD-ERK1 showed a weak, dose-dependent inhibition of MEK1SS3 signaling to the cyclin D1 reporter gene, whereas inhibition was more pronounced with KD-ERK2 ( Figure 2d ). Cotransfection of KD-ERK1 and 2 did not significantly increase the negative effect observed with KD-ERK2 alone (data not shown). In the absence of MEK1SS3, KD-ERK2 slightly reduced cyclin D1 reporter activity (data not shown), suggesting some contribution of the ERK2 cascade to basal activity in 0.5% serum. Taken together, these data indicate that the ERK5 cascade can specifically induce the cyclin D1 promoter to a similar degree as that observed with the ERK1/2 pathway.
The major CRE in the cyclin D1 promoter mediates induction by the ERK5 cascade
We next asked which of the multiple regulatory elements in the cyclin D1 promoter are targeted functionally by ERK1/2 and ERK5. In some cells, the ERK1/2 and ERK5 cascades activated expression of a reporter gene controlled by NF-kB binding sites (Pearson et al., 2001) . Moreover, NF-kB has been implicated in the regulation of cyclin D1 reporter activity by diverse proliferative signals through two recognition sites in the proximal and distal regions of the cyclin D1 promoter (Figure 4a ) (Guttridge et al., 1999; Hinz et al., 1999; Henry et al., 2000; Page et al., 2002) . In CCL39 cells, mutations in both NF-kB sites diminished cyclin D1 reporter activation by ERK1/2 and ERK5 (Mulloy and Hipskind, manuscsript in preparation). Curiously, NF-kB appears to repress cyclin D1 reporter activity in this context, as it does in airway smooth muscle cells (Page et al., 2002) .
The CRE located at position À50 in the cyclin D1 promoter (Figure 4a ) mediates induction by diverse signals in different cell types (Herber et al., 1994; Beier et al., 1999; Joyce et al., 1999; Lee et al., 1999; D'Amico et al., 2000; Page et al., 2002) . A major mechanism of CRE activation is signal-driven phosphorylation of The various transfected kinases are expressed at similar levels. Whole-cell extracts were prepared from untransfected CCL39 cells (labeled NT) or cells transfected with the indicated kinase expression vectors, and the kinases visualized by immunoblotting with antibodies specific for their epitope tags, namely HA for MEK1SS3, MEK5D, and KD ERK1 and 2 or FLAG for ERK5 and ERK5AEF. In the reporter gene assays, induction was calculated relative to the reporter gene without added kinase vectors, and the data are expressed as mean7s.e.m. *Po0.05 relative to the reporter gene alone, ANOVA/NewmanKeuls; Po0.05 relative to the reporter gene plus activated kinase, ANOVA/Newman-Keuls. The results are representative of at least three independent experiments, each performed in duplicate Ser133 in the CRE binding protein CREB, and the subsequent recruitment of the coactivator CBP (Janknecht and Hunter, 1996) . CREB, and therefore the CRE, can potentially be targeted by the ERK1/2 cascade via activation of the kinases RSK and MSK (Xing et al., 1996; Deak et al., 1998) , as well as via MEK5-ERK5-RSK signaling module (Pearson et al., 2001 ). Therefore, we tested the role of CREB and CRE in cyclin D1 induction by these two pathways in CCL39 cells. Initially, we cotransfected the wt cyclin D1 reporter gene with wt CREB or CREB bearing a Ser133Ala mutation that blocks its phosphorylation. The CREB expression vector led to a strong, dose-dependent activation of the cyclin D1 reporter (Figure 4b and c) . In addition, the CREB Ser133Ala mutant still transactivated this reporter gene, albeit to a lower level than that of wt CREB (12-fold versus 20-fold, respectively, Figure 4b ). Given this unexpected result, we confirmed that the mutant version of CREB did indeed compromise activation signals normally targeting Ser133 by cotransfecting the catalytic subunit of PKA under the same conditions as above. Active PKA enhanced activation of the cyclin D1 reporter by wt CREB. In contrast, the Ser133Ala mutation completely blocked PKA-driven activation (Figure 4b ), suggesting that overexpression of the catalytic subunit of PKA overrides the mechanisms regulating the cyclin D1 reporter under our basal conditions. Thus, classical CREB induction based on Ser133 phosphorylation is active in CCL39 cells. Nevertheless, under certain conditions, transactivation of the cyclin D1 promoter by CREB is largely independent of signal-driven phosphorylation of Ser133.
To insure that activation was specific for the CRE at À50 in the cyclin D1 promoter, we tested a promoter with mutations in the CRE (see diagram in Figure 4a ) that block CREB binding and thus activation (Boulon et al., 2002) . This CRE mutant strongly decreased transactivation by CREB at two different concentrations of expression vector (Figure 4c ). We then tested the effect of the mutant CRE on cyclin D1 reporter induction by cotransfection of constitutively activated MEK1 or MEK5 together with ERK5. Mutation of the CRE did not affect reporter activation by MEK1SS3, while it completely abolished induction by MEK5D/ ERK5 (Figure 4d ). These data suggest that the ERK5 cascade targets the cyclin D1 CRE in CCL39 cells.
To examine the role of CREB, we tested the effect of cotransfecting the ERK5 cascade components together with expression vectors for either wt or mutant CREB. CREB Ser133Ala blocked CREB-driven transactivation linked to phosphorylation-dependent recruitment of the coactivators CBP/p300, while A-CREB is a dominantnegative inhibitor of CREB DNA binding and activity (Ahn et al., 1998) . CREB Ser133Ala increased cyclin D1 reporter activation by the MEK5D/ERK5 cascade module to the same extent as wt CREB, whereas A-CREB blocked activation (Figure 4e ). These data indicate that CREB binding to the CRE, but not Ser133 phosphorylation, was required for ERK5 induction of the cyclin D1 promoter.
Cyclin D1 AP-1 site is not required for activation by either MAPK cascade
The cyclin D1 AP-1 site (À930 relative to the RNA initiation site, Figure 4a ) has also been implicated in ERK1/2 induction of cyclin D1 in multiple cultured cell lines (Albanese et al., 1995 ; Balmanno and Cook, Figure 3 Endogenous cyclin D1 protein expression is activated by MEK1SS3 or MEK5D/ERK5 and repressed by ERK5AEF. (a) CCL39 cells plated on coverslips were either left in serum (asynchronous), serum starved or stimulated with 15% serum for 7 h, as indicated. After fixation and permeabilization, cyclin D1 protein and nuclei were visualized as described in Materials and methods. The panels show Hoechst-stained nuclei (blue) and endogenous cyclin D1 protein (red). (b) CCL39 cells were transfected with expression vectors for HA-MEK1SS3 or HA-MEK5D along with either FLAG-ERK5 or FLAG-ERK5AEF. The following day, medium was changed to 0.5% serum for an additional day before visualization. Transfected cells (green) were visualized using HA-and FLAG-specific antibodies. Nuclei and endogenous cyclin D1 are presented as described above. (c) Cells were transfected with FLAG-ERK5AEF, then serum-starved and induced as in part (a). Transfected cells (green), nuclei (blue) and endogenous cyclin D1 (red) were detected as described above. The white arrows indicate transfected cells. The panels shown are representative of several fields on the coverslip, and the results are representative of at least three independent experiments 1999; Bakiri et al., 2000) . To evaluate its role in induction by the ERK1/2 and ERK5 cascades under our transfection conditions, we tested a cyclin D1 reporter gene containing a mutated AP-1 site (see diagram in Figure 4a ) in the presence of MEK1SS3or MEK5D-ERK5. The TRE mutant was activated similar to the wt cyclin D1 reporter by either constitutively activated cascade (Figure 4f ). Thus, under our conditions, the AP-1 site was not the principal mediator of cyclin D1 reporter activation by ERK1/2 or ERK5.
Erk5 phosphorylation is not induced by serum in a variety of breast-tumor-derived cell lines
In light of the link between cyclin D1 overexpression and breast cancer, along with the above observations Figure 4 The cyclin D1 CRE, unlike the TRE, is targeted by the ERK5 cascade. (a) Schematic diagram showing a subset of the regulatory elements in the human cyclin D1 promoter (not to scale). (b) The wt D1 À973 luciferase reporter gene was transfected alone or with expression vectors for wt CREB (100 ng), CREB Ser133Ala (100 ng) and the catalytic subunit of PKA (50 ng), as indicated below the bar graph, (c) Wt or mutant CRE cyclin D1 reporter genes were transfected alone or together with 50 ng ( þ ) or 100 ng ( þ þ ) of the wt CREB expression vector. (d) Wt or mutant CRE cyclin D1 reporter genes were transfected alone or together with expression vectors for MEK1SS3 or MEK5D and ERK5, as indicated. (e) The wt cyclin D1 reporter gene was transfected either alone or with MEK5D and ERK5. In addition, 50 ng of wt CREB, CREB Ser133Ala or A-CREB was added as indicated. (f) The wt or mutant AP-1 (TRE mut) cyclin D1 reporter gene was transfected alone or together with expression vectors for MEK1SS3, or MEK5D and ERK5, as indicated. The induction was calculated relative to the reporter gene without added kinase or transcription factor, and the data are expressed as mean7s.e.m. *Po0.05 relative to the wt or mutant reporter gene alone, ANOVA/Newman-Keuls; #Po0.05 relative to the reporter gene plus activated kinase, ANOVA/Newman-Keuls; O Po0.05 relative to the reporter gene plus activated kinase plus wt CREB, ANOVA/Newman-Keuls. The results are representative of at least three independent experiments, each performed in duplicate implicating ERK5 in cyclin D1 transcriptional activation, we investigated the induction of ERK5 phosphorylation by serum in the mammary epithelium cell line MCF10A and a panel of breast-cancer-derived cell lines. Initially, we visualized endogenous ERK5 in whole-cell extracts prepared from various tumor cell lines. Immunoblotting showed comparable levels of ERK5 in the following cell lines: MCF10A; the breast cancer cell lines MCF7, MDA-MB-231, and T47D; the cervical carcinoma cell line HeLa and the human osteosarcoma cell line HOS/TE85 (Figure 5a ). Equivalent levels of ERK1 and 2 were also present in all lanes (data not shown). We then asked whether serum treatment induced ERK5 phosphorylation in MCF10A cells and the breast cancer cell lines HS578 T, MCF7, MDA-MB-231 and -435, T47D and ZR-75-1. Immunoblots contained extracts prepared from cells growing asynchronously in 10% serum, cells left in 0.5% serum for 36 h and starved cells treated with 15% serum for 30 min. Phospho-ERK5 was readily detected in extracts from asynchronously growing MCF10A, HS578 T and MDA-MD-231 cells, but not from the other cell lines (Figure 5b ). Asynchronous MDA-MD-231 cells also contained high levels of phospho-ERK1/2, while moderate levels were seen in the HS578 T, MCF7 and T47D extracts. Prolonged incubation in 0.5% serum reduced phospho-ERK5 levels in MCF10A cells and in MDA-MB-231 cells without affecting phospho-ERK5 in the other cell lines. Similarly, serum starvation reduced phospho-ERK1/2 levels in MCF10A cells and had a modest effect in MCF7 cells (Figure 5b) . Addition of 15% serum did not stimulate ERK5 phosphorylation in any of the cell lines, whereas serum induced ERK1/2 phosphorylation in all of the cell lines except for MDA-MB-231 (Figure 5b ). These data indicate that in these cell lines, ERK5 shows constitutive activity, as measured by its phosphorylation. Notably, this was not rapidly induced by serum addition, unlike the phosphorylation of ERK1/2.
Dominant-negative ERK5 blocks constitutive cyclin D1 protein expression in breast-cancer-derived cell lines
We asked whether the above observations might reflect a continuous state of activation in these cell lines that is insensitive to serum withdrawal, outside of the ERK1/2 cascade. Consistent with this interpretation, nuclear cyclin D1 protein immunofluorescence was readily detectable in HS578 T, MCF7, MDA-MB-231 and -435, and ZR-75-1 cells subjected to serum starvation (Figure 6a ). To test the role of ERK5 on cyclin D1 protein expression in these cells, we transiently transfected the expression vector for kinase-dead ERK5 (ERK5AEF). In HS578 T and MCF7 cells that were serum treated for 8 h to maximize cyclin D1 protein induction, cells expressing ERK5AEF showed decreased levels of cyclin D1 immunofluorescence (indicated by arrows in Figure 6b ) relative to the neighboring, untransfected cells. Thus, despite the apparent unresponsiveness of ERK5 to serum stimulation in breast cancer cell lines, dominant-negative ERK5 blocks expression of the endogenous cyclin D1 protein, indicating that the ERK5 cascade is part of the network regulating cyclin D1 expression in this context.
Discussion
In this paper, we demonstrate that in CCL39 cells, the ERK5 cascade targets the cyclin D1 promoter, activating it to the same degree as the ERK1/2 pathway. We performed transient transfections using constitutively activated mutants of MEK5 and MEK1 that are specific for the ERK5 and ERK1/2 cascades, respectively. Both activated kinases increased endogenous cyclin D1 protein levels and trans-activated the cyclin D1 promoter. Unlike MEK1SS3, the stimulatory effect of MEK5D required coexpression with ERK5 and was blocked by a kinase-dead form of ERK5. Notably, Whole-cell extracts were prepared from asynchronously growing cells from the following cell lines: MCF10A-mammary epithelium, MCF7, MDA-MB 231 and T47D-mammary carcinoma, HeLacervical carcinoma and TE85-osteosarcoma. Protein (30 mg) was loaded on SDS-PAGE minigels, transferred to nitrocellulose and detected with ERK5-specific antiserum. (b) Whole-cell extracts were prepared from MCF10A cells and the indicated mammary carcinoma cell lines left continuously growing in serum (labeled A for asynchronous), serum-starved (S) or starved then serum stimulated (Stim). Immunoblotting was performed using phospho-ERK5 antiserum (P-ERK5) that also detects phospho-ERK1/ 2 (P-ERK1/2), as described above. The panels show the relevant regions of the immunoblots Figure 6 Numerous breast cancer cell lines constitutively express cyclin D1 protein, which is blocked by kinase-dead ERK5AEF in MCF7 and HS578 T cells. (a) The indicated cell lines were plated on coverslips, then subjected to serum deprivation for 24 h prior to fixation, permeabilization and staining for cyclin D1 protein and nuclei as described in the legend to Figure 3 . The panels show Hoechst-stained nuclei (blue) and endogenous cyclin D1 protein (red). (b) HS578 T and MCF7 cells were plated on coverslips and transfected with the ERK5AEF expression vector. After 1 day of serum starvation, cells were induced with 15% serum for 8 h, followed by fixation and permeabilization. Endogenous cyclin D1 (red), FLAG-ERK5AEF (green) and nuclei (blue) were visualized as described in the legend to Figure 3 . The white arrows indicate the transfected cells. The panels shown are representative of several fields on the coverslip ERK5 activates cyclin D1 expression R Mulloy et al kinase-dead ERK5 strongly reduced serum induction of endogenous cyclin D1 protein expression in CCL39 cells, as well as constitutive cyclin D1 protein expression in several breast cancer cell lines. To our knowledge, this is the first link between ERK5 and cyclin D1 induction. Consistent with previous studies (Lavoie et al., 1996) , transfection of activated MEK1 was sufficient to induce the cyclin D1 promoter, indicating that the endogenous pool of ERK can mediate activation by ectopic MEK1, which is not the case for MEK5D. Coexpression of a kinase-dead ERK2 mutant fully blocked induction by activated MEK1, while kinase-dead ERK1 had a minor effect, indicating that, in this context, an MEK1SS3-ERK2 signaling module targets the cyclin D1 promoter. Similarly, kinase-dead ERK2 blocks cyclin D1 reporter activation in human trophoblasts and mink lung epithelial cells (Albanese et al., 1995) . On the other hand, a different kinase-dead ERK1 mutant (ERK1 T192A) diminishes serum stimulation of a cyclin D1 reporter in CCL39 cells (Lavoie et al., 1996) . This discrepancy likely reflects the different experimental conditions, including the effect of selective activation with MEK1SS3 versus the multiple signaling pathways induced by serum.
To identify the promoter elements targeted by these cascades, we analysed the induction of reporter genes with mutated CRE or AP-1 sites. The CRE is constitutively occupied in genomic footprints performed in WI-38 cells (Herber et al., 1994) , and accordingly is an important positive and negative mediator of cyclin D1 transcriptional control in numerous cell lines. Its mutation diminishes cyclin D1 reporter induction by serum in NIH3T3 cells and primary mouse embryo fibroblasts (Herber et al., 1994; Brown et al., 1998) , by PDGF in airway smooth muscle cells (Page et al., 2002) , by activated Rac1 in NIH3T3 cells (Joyce et al., 1999) and by v-Src in MCF-7 cells, in which the ERK, SAPK and p38 cascades are all implicated as intermediates via phosphorylation of CREB and ATF-2 . In contrast, we found that in CCL39 cells, mutation of the CRE did not affect activation by MEK1SS3, but it strongly compromised activation by the ERK5 cascade. Furthermore, coexpression of CREB enhanced this activation whereas it was blocked by dominant-negative CREB. CREB activity is strongly potentiated by MAPK cascade-mediated phosphorylation on Ser133. However, this is normally a rapid, transient event that occurs long before the window of cyclin D1 induction, and accordingly a CREB Ser133Ala mutant does not significantly diminish cyclin D1 activation by any intracellular messenger other than PKA in either MCF-7 or CCL39 cells (Boulon et al., 2002 and our data) . Instead, in MCF-7 cells, CREB activates the cyclin D1 promoter in a phosphorylation-and CBP-independent manner via a higher order complex involving Oct-1 (Boulon et al., 2002) . Our data suggest that a similar mechanism functions in CCL39 cells, either via Oct-1 or a stillunidentified partner that could be a target of the ERK5 cascade. One potential candidate is c-Jun, since its promoter is activated by ERK5 phosphorylation of MEF2C (Kato et al., 1997) . Interestingly, transactivation of cyclin D1 by overexpressed c-Jun is blocked by mutating the CRE in NIH3T3 and HeLa cells (Herber et al., 1994; Bakiri et al., 2000) .
In contrast to the CRE, we found that mutation of the AP-1 site at À930 in the cyclin D1 promoter did not affect activation by either the ERK1/2 or ERK5 pathway. Consistent with our observations, the AP-1 site is not required for induction in other cell types, for example, by serum in NIH3T3 cells or by the v-Src/ multiple MAPK cascade signaling system in MCF-7 cells (Herber et al., 1994; Lee et al., 2000) . This is unexpected, since ERK1/2 elevates the expression of several components of AP-1, while ERK5 activates the c-jun promoter (Kato et al., 1997) . Moreover, activated Ras and overexpressed c-Jun induce the cyclin D1 promoter exclusively through the AP-1 site in JEG-3 cells (Albanese et al., 1995) , or through this element and the CRE in HeLa cells (Bakiri et al., 2000) . Notably, in the latter study, repression by JunB also required the AP-1 site as well as the CRE. Despite these studies, our data clearly indicate that if ERK5 induction of cyclin D1 in CCL39 cells does involve c-Jun, the AP-1 site does not play a crucial role. It is important to stress that, while we have identified an element in the cyclin D1 promoter targeted by ERK5, this is merely one component in a complex regulatory network that most likely involves several signaling pathways.
Ectopically expressed ERK5 plays a role in EGFinduced proliferation of the mammary epithelial cell line MCF10A (Kato et al., 1998) . In asynchronously growing MCF10A cells, we readily detected endogenous ERK5, a portion of which showed activating phosphorylation. Levels of phospho-ERK5 were decreased by serum starvation and did not increase upon serum stimulation, unlike those of phospho-ERK1/2. Thus, it is possible that ERK5 activation is specific to EGF in this cell line, and that the high level of phospho-ERK5 observed during asynchronous growth might reflect an autocrine stimulation loop. It is also possible that serum induces a recently described kinase that appears to be closely related to ERK5. Interestingly, despite high levels of ERK5, none of the breast cancer cell lines examined here showed any difference in phospho-ERK5 levels between asynchronous, serum-starved or serumstimulated conditions. Nevertheless, the ERK1/2 pathway remained fully inducible by serum. One possible explanation is that oncogenic transformation has affected regulation of the ERK5 cascade to yield a low level of constitutive activation that would in turn contribute to deregulated cyclin D1 expression. Consistent with this idea, breast cancer cell lines that overexpress activated forms of ErbB2-4 show constitutive ERK5 activation, and kinase-dead ERK5 blocks proliferation (Esparis-Ogando et al., 2002) . Moreover, we find that kinase-dead ERK5 decreases cyclin D1 levels in asynchronous and serum-starved MCF7 and HS578 T cells. Thus, the ERK5 cascade seems to play an important role in normal and abnormal proliferation of mammary epithelium that we argue is linked to the regulation of the cyclin D1 gene. Furthermore, ERK5
ERK5 activates cyclin D1 expression R Mulloy et al may be involved in cyclin D1 overexpression that is a hallmark of breast cancer. This hypothesis will be addressed in future studies.
Materials and methods
Antibodies and reagents
The antibodies used were anti-cyclin D1 mAB (Western blotting, 1 : 300; BD Biosciences/Pharmingen via Ozyme, St Quentin Yvelines, France), anti-phospho-Thr202/Tyr204 ERK1/2, anti-Erk1/2 and anti-phospho-Thr218/Tyr220 ERK5 (1 : 1000; Cell Signaling Technologies via Ozyme), anti-ERK5 (1 : 1000; Upstate Biotechnologies Inc. /Euromedex, Mundholsheim, France) and anti-FLAG M2 mAb (Sigma-Aldrich, Saint Quentin Fallavier, France). The anticyclin D1 rabbit antibody used for indirect immunofluorescence was kindly provided by Dr Vjekoslav Dulic of the CRBM (Montpellier, France), and the anti-HA mAb was a gift from Dr Ralf Janknecht (Mayo, Rochester, MN, USA). Luciferase assay reagent was purchased from Promega, France (Charbonnie`res, France).
Plasmids
The luciferase reporter gene driven by the cyclin D1 promoter fragment spanning from À973 to þ 139 was kindly provided by R Mueller (Herber et al., 1994) . The cyclin D1 CRE mut has been previously described (Boulon et al., 2002) . The cyclin D1 reporter bearing a mutated AP-1 site (Herber et al., 1994) was obtained from M Yaniv. The expression vectors for MEK5D, ERK5 and ERK5AEF (Kato et al., 1997) were graciously provided by J-D Lee, MEK1SS3 (Brunet et al., 1994) by J Pouyssegur via P Roux, and ERK1K71R and ERK2K52R by M Cobb. The c-jun wt and mutant promoter constructs (Han and Prywes, 1995) were kind gifts from R Prywes. The CMV b-Gal plasmid was kindly provided by C Sardet, the pBabe vector was a gift from M Classon and the cyclin D1 cDNA clone was a gift from P Sicinski.
Cell culture
All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Invitrogen, Cergy Pontoise, France), and 0.2 mm. l-glutamine at 371C, 5% CO 2 . The Chinese hamster lung fibroblast cell line CCL39 was graciously provided by C Sardet. The human breast cancer cell lines MCF7, MDA-MB-435, HS58 T, ZR and T47D were obtained from A Gartland. The MDA-MB-231 human breast cancer cell line was a kind gift from P Coopman.
Cell lysate preparation and immunoblots
Cells were washed twice with ice-cold phosphate-buffered saline (PBS, 140 mm NaCl, 2.7 mm. KCl, 8.1 mm Na 2 HPO 4 , 1.5 mm KH 2 PO 4 (pH 7.3)) containing 10 mm NaF and 100 mm Na 3 VO 4 , and scraped off in lysis buffer (10 mm Tris-HCl, 50 mm NaCl, 50 mm NaF, 1% Triton X-100 (w/v), 30 mm Na 4 P 2 O 7 , 5mm ZnCl 2 , 20mm b-glycerophosphate, 10 mm 4-nitrophenyl phosphate, titrated to pH 7.05 (Hipskind et al., 1994) ). The following components were added fresh from stock solutions immediately prior to cell lysis: 1 mm dithiothreitol (DTT), 100 mm Na 3 VO 4 , 50 nm okadaic acid, 0.5 mm benzamidine, 0.5 mm phenylmethylsulfonyl floride (PMSF) and 2.5 mg/ml each aprotinin, leupeptin, pepstatin and antipain. Lysis was completed by vortexing and the lysates cleared by centrifugation at 12 000 Â g for 30 min at 41C. Protein concentrations were determined with Bradford's reagent using bovine serum albumin (BSA) as the standard. Aliquots were mixed with 4 Â Laemmli sample buffer (250 mm Tris-HCl, pH 6.8, 10% sodium dodecyl sulfate (SDS) (w/v), 10% glycerol, 5% 2-mercaptoethanol, 0.001% bromphenol blue (w/v) and denatured immediately for protein immunoblot analyses.
Denatured extracts were subjected to SDS-PAGE on 7.5% (ERK5) or 10% (cyclin D1, ERK1/2) minigels. Proteins were transferred onto Protran nitrocellulose (Schleicher and Schuell, Dassel, Germany) by immersion blotting and the membranes blocked for 1 h at RT in either 5% BSA-TBST (100 mm NaCl, 10 mm Tris-HCl (pH 7.5), 0.05% Tween 20 (w/v)) for phosphospecific antisera or 5% low-fat milk-TBST for other antisera. The membranes were incubated overnight at 41C with the antiserum indicated in the figures, diluted 1 : 1000 into blocking buffer. After extensive washing in TBST, membranes were incubated for at least 1 h at RT with peroxidase-coupled secondary antiserum diluted in 5% lowfat milk-TBST (1 : 5000 for anti-rabbit, 1 : 1000 for antimouse). After further washing, the immunocomplexes were revealed by enhanced chemiluminescence (Western Lightening Plus, Perkin-Elmer Life Sciences, Courtaboeuf, France).
RNA analysis
Total cell RNA was prepared with TRIzol reagent (Invitrogen) according to the manufacturer's instructions. RNA (7.5 mg) was electrophoresed in 0.8% agarose-3.7% formaldehyde gels and transferred to Zetabind nylon membranes (Cuno, Meridient, CT, USA). The filters were prehybridized and hybridized at 651C in 50% formamide, 5 Â SSC (1 Â SSC is 150 mm NaCl, 15 mm sodium citrate, pH 7.0), 5 Â Denhardt's solution, 1% SDS, 50 mm NaPO 4 (pH 6.8), 5 mg/ml total calf liver RNA and 5 mg/ml Torula RNA. cRNA probes were prepared from mouse cyclin D1 and rat gapdh cDNA plasmids, and hybridized for at least 16 h, followed by washing at 651C in 0.2 Â SSC-1% SDS. Signals were detected by autoradiography and phosphorimagery.
Transient transfections and luciferase assays
CCL39 cells were seeded at 1 Â 10 6 per well in six-well plates 1 day prior to transfection. The medium was changed 1 h before tranfection which was performed using Fugene 6 Reagent (Roche, Meylan, France). For all tranfection assays, 250 ng of reporter was used along with 500 ng of each MAPK construct unless otherwise indicated. pCMV b-Gal (50 ng) was cotransfected as internal control and pBabe was used to equalize total DNA content to 1-1.5 mg. The following day, medium was changed to 0.5% FCS for 1 day. Transfections were harvested after 1 day of starvation, cells were lysed and luciferase assays were performed according to the manufacturer's instructions (Promega, Charbonnie`res, France) using a Berthold luminometer. b-Galactosidase levels were measured as previously described (Hateboer et al., 1998 ) using a Dynex MRX TC microtiter plate reader. Luciferase values were divided by those of b-gal to normalize for transfection efficiency. Data were expressed as mean7s.e.m. Statistical significance was evaluated with one-way ANOVA coupled to the Newman-Keuls multiple range test using WINKS Statistical Data Analysis software (TexaSoft, Cedar Hill, TX, USA).
Immunofluorescence staining and microscopy
Cells were plated on 12 mm glass coverslips and transfected as described. The following morning, cells were placed in DMEM containing 0.5% FCS for 1 day. After 24 h, the cells were stimulated for 8 h with 15% FCS. Cells were fixed in 3.7% formalin in PBS for 10 min at RT, washed in PBS, permeabilized in 0.1% Triton in PBS for 5 min at RT and rinsed again in PBS. Nonspecific reactivity was blocked by incubating in 3% BSA for 15 min at RT, and then coverslips were incubated for 1 h at RT with anti-cyclin D1 affinitypurified polyclonal antibody diluted 1 : 50 in 3% BSA and either anti-FLAG mAB (1 : 250) or anti-HA mAb (1 : 10). After washing, the coverslips were incubated for 1 h at RT in the dark with a mix containing an anti-mouse IgG-FITC conjugate (1 : 200), anti-rabbit IgG conjugated to CY3 (1 : 1000) and Hoechst 33342 (100 ng/ml) (all three from Sigma-Aldrich, Saint Quentin Fallavier, France). After further rinses, the coverslips were mounted with Fluoprep (BioMerieux, Marcy l'Etoile, France) and visualized using a Leica DMRA microscope.
